Zydus Lifesciences Drug Patent Portfolio

Zydus Lifesciences's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Zydus Compensates Astellas $120 Million to Resolve US Patent Dispute Over Generic Medication - Whalesbook

12 Feb, 2026

Zydus resolves patent conflict over Mirabegron with Astellas for $120 million in the US.

12 Feb, 2026

Zydus Lifesciences settles US patent conflict over bladder medication for $120 million.

12 Feb, 2026

Supreme Court refuses to stop Zydus from marketing its cancer drug biosimilar, advises Bristol Myers to seek relief from High Court.

11 Feb, 2026